Literature DB >> 25738422

Health Care Utilization, Patient Costs, and Access to Care in US Adults With Eczema: A Population-Based Study.

Jonathan I Silverberg1.   

Abstract

IMPORTANCE: Little is known about the health burden of adult eczema in the United States.
OBJECTIVE: To study the out-of-pocket costs, health care access and utilization in adult eczema in the United States. DESIGN, SETTING, AND PARTICIPANTS: Two US population-based studies, the 2010 and 2012 National Health Interview Surveys, surveyed 27 157 and 34 613 adults (ages 18-85 years). EXPOSURES: History of eczema. MAIN OUTCOMES AND MEASURES: The out-of-pocket costs, lost workdays, days in bed, and access to care.
RESULTS: Adults with eczema had $371 to $489 higher out-of-pocket costs per person-year compared with those without eczema, with higher odds of increased out-of-pocket costs (survey multinomial logistic regression, adjusted odds ratios [ORs] [95% CIs] for NHIS 2012, <$1 to 499: OR, 1.27; 95% CI, 1.05-1.54; $500 to $1999: OR, 1.49; 95% CI, 1.22-1.81; $2000-$2999: OR, 1.74; 95% CI, 1.36-2.21; $3000-$4999: OR, 2.07; 95% CI, 1.56-2.73; ≥$5000: OR, 1.74; 95% CI, 1.34-2.27; P < .001). Adults with eczema were significantly more likely to have at least 6 lost workdays from all causes (OR, 1.53; 95% CI, 1.26-1.84), 1 to 2 half-days (OR, 1.31; 95% CI, 1.14-1.51); 3 to 5 half-days (OR, 1.84; 95% CI, 1.54-2.20), and at least 6 half-days (OR, 2.24; 95% CI, 1.92-2.62) in bed and increased health care utilization with more physician visits (1-3 visits: OR, 1.70; 95% CI, 1.40-2.07; 4-9 visits: OR, 2.45; 95% CI, 2.00-3.00; and ≥10 visits: OR, 3.33; 95% CI, 2.69-4.12), urgent or emergency care visits (1-3 visits: OR, 1.46; 95% CI, 1.29-1.66; 4-9 visits: OR, 1.81; 95% CI, 1.27-2.57; and ≥10 visits: OR, 2.43; 95% CI, 1.19-4.99) and hospitalizations (OR, 1.37; 95% CI, 1.17-1.60). Adults with eczema had significantly limited access to care with inability to afford prescription medications (OR, 2.36; 95% CI, 1.92-2.81), were unable to get an appointment soon enough (OR, 2.04; 95% CI, 1.73-2.41), had to wait too long to see a physician (OR, 1.59; 95% CI, 1.28-1.97), had delayed care (OR, 1.73; 95% CI, 1.49-2.01), and were not able to get care (OR, 1.66; 95% CI, 1.40-1.97) because of worry about the related costs. CONCLUSIONS AND RELEVANCE: This study demonstrates a large health burden of eczema in adults and suggests substantial out-of-pocket costs, indirect costs from lost workdays and sick days, and increased health care utilization.

Entities:  

Mesh:

Year:  2015        PMID: 25738422     DOI: 10.1001/jamadermatol.2014.5432

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  20 in total

1.  Association between Atopic Dermatitis and Depression in US Adults.

Authors:  Sherry H Yu; Jonathan I Silverberg
Journal:  J Invest Dermatol       Date:  2015-08-28       Impact factor: 8.551

2.  Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults.

Authors:  M A Strom; A B Fishbein; A S Paller; J I Silverberg
Journal:  Br J Dermatol       Date:  2016-08-28       Impact factor: 9.302

3.  Breastfeeding duration modifies the effect of smoking during pregnancy on eczema from early childhood to adolescence.

Authors:  Nandini Mukherjee; Thomas R Sutter; Syed Hasan Arshad; John W Holloway; Hongmei Zhang; Wilfried Karmaus
Journal:  Clin Exp Allergy       Date:  2018-12       Impact factor: 5.018

4.  Inflammatory skin disorders and self-esteem.

Authors:  C Y Yang; A S Kourosh
Journal:  Int J Womens Dermatol       Date:  2017-10-21

5.  Assessment of atopic dermatitis using self-report and caregiver report: a multicentre validation study.

Authors:  J I Silverberg; N Patel; S Immaneni; B Rusniak; N B Silverberg; R Debashis; N Fewkes; E L Simpson
Journal:  Br J Dermatol       Date:  2015-10-23       Impact factor: 9.302

6.  Validation of International Classification of Disease Ninth Revision codes for atopic dermatitis.

Authors:  D Y Hsu; P Dalal; K A Sable; N Voruganti; B Nardone; D P West; J I Silverberg
Journal:  Allergy       Date:  2017-01-17       Impact factor: 13.146

Review 7.  Evaluating the Longitudinal Course of Atopic Dermatitis: Implications for Clinical Practice.

Authors:  Raj Chovatiya; Jonathan I Silverberg
Journal:  Am J Clin Dermatol       Date:  2022-05-31       Impact factor: 6.233

8.  TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries.

Authors:  Louise A A Gerbens; Aaron E Boyce; Dmitri Wall; Sebastien Barbarot; Richard J de Booij; Mette Deleuran; Maritza A Middelkamp-Hup; Amanda Roberts; Christian Vestergaard; Stephan Weidinger; Christian J Apfelbacher; Alan D Irvine; Jochen Schmitt; Paula R Williamson; Phyllis I Spuls; Carsten Flohr
Journal:  Trials       Date:  2017-02-27       Impact factor: 2.279

Review 9.  The Challenge of Managing Atopic Dermatitis in the United States.

Authors:  Steven R Feldman; Linda S Cox; Lindsay C Strowd; Robert A Gerber; Steven Faulkner; Debra Sierka; Timothy W Smith; Joseph C Cappelleri; Mark E Levenberg
Journal:  Am Health Drug Benefits       Date:  2019-04

Review 10.  Histamine and Skin Barrier: Are Histamine Antagonists Useful for the Prevention or Treatment of Atopic Dermatitis?

Authors:  Anna De Benedetto; Takeshi Yoshida; Sade Fridy; Joo-Eun S Park; I-Hsin Kuo; Lisa A Beck
Journal:  J Clin Med       Date:  2015-04-21       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.